3 8 4 8 0

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊










更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

已发表论文

药物治疗急性髓细胞白血病(急性早幼粒细胞白血病除外)的进展

 

Authors Lin M, Chen B

Received 31 December 2017

Accepted for publication 8 March 2018

Published 30 April 2018 Volume 2018:12 Pages 1009—1017

DOI https://doi.org/10.2147/DDDT.S161199

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Palas Chanda

Peer reviewer comments 2

Editor who approved publication: Professor Manfred Ogris

Abstract: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years.
Keywords: acute myeloid leukemia, new drug therapies, refractory/relapsed AML, 2017 NCCN guideline